Optimal use of lenvatinib in the treatment of advanced thyroid cancer

Table 2 Major adverse events associated with lenvatinib

		Hypertension	Diarrhea	Fatigue	PPE	Proteinuria	Thrombocytopenia
Phase III (general population) (n = 261) [2]	Any grade	68	59	59	32	31	9
Phase III (general population) (n = 261) [2]	Grade ≥ 3	42	8	9	3	10	2
Phase III (Japanese population) (n = 30) [7]	Any grade	87	60	60	70	63	47
Phase III (Japanese population) (n = 30) [7]	Grade ≥ 3	80	0	13	3	20	7

Events are listed in order of the most frequent events of any grade in the general population
Data are shown as incidence (%). PPE, palmar–plantar erythrodysesthesia

ISSN: 2059-7347